ACADIA Pharmaceuticals Inc. (ACAD)
Symbol Info
Listed Symbol ACAD
Name ACADIA Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $223,807,000
Latest Fiscal EPS $-1.95
Price Info
21 Day Moving Average $39.5286
21 Day EMA $38.100090
50 Day Moving Average $33.9148
50 Day EMA $34.826870
200 Day EMA $28.115720
200 Day Moving Average 26.796000
52 Week High $44.85
52 Week Low $14.01
52 Week Change $93.044300
Alpha 0.002512
Beta 2.7756
Standard Deviation 0.181736
R2 0.275367
Periods 60
Share Information
10 Day Average Volume 1,714,966
20 Day Average Volume 2,362,682
30 Day Average Volume 3,087,508
50 Day Average Volume 2,302,288
Outstanding Shares 144,487,428
Float Shares 143,929,717
Percent Float 99.61%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 458
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 4,886,996
Institute Holdings Percent -
Institute Sold Previous 3 Months 9,155,843
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 0.40%
Insider Sold Previous 3 Months 4
Insiders Shares Owned 557,711
Price Change
7 Day Price Change $2.3600006
7 Day Percent Change 6.18%
21 Day Price Change $-0.2200012
21 Day Percent Change -0.54%
30 Day Price Change $-0.8699989
30 Day Percent Change -2.10%
Month To Date Price Change $4.5300
Month To Date Percent 12.59%
90 Day Price Change $13.270000
90 Day Percent Change 48.70%
Quarter To Date $4.529999
Quarter To Date Percent 12.59%
180 Day Price Change $14.500000
180 Day Percent Change 55.73%
200 Day Price Change $14.330000
200 Day Percent Change 54.72%
Year To Date $24.350000
Year To Date Percent 150.59%
Profile
Description Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Details
Issue Type CS
Market Cap $5,854,630,583
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 144,487,428
CEO Stephen R. Davis
Employees 477
Last Audit UQ
Classification
CIK 0001070494
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 3611 Valley Centre Drive
Suite 300
San Diego, CA 92130
Website http://www.acadia-pharm.com
Facisimile +1 858 558-2872
Telephone +1 858 558-2871
Email ir@acadia-pharm.com
Key Ratios
Profitability
EBIT Margin -103.5
EBITDA Margin -102.4
Pre-Tax Profit Margin -69,599.6
Profit Margin Cont -
Gross Margin 95.20
Profit Margin TOT -
Income Statements
Revenue $205,735,000
Revenue Per Share $1.4239
Revenue 3 Years $181.09
Revenue 5 Years $498.23
Valuation Measures
PE Ratio -
Enterprise Value $4,829,369,533
Price To Sales 28.457144
Price To Free Cash -37.8
PE High Last 5 Years -
Price To Book 13.9
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 13.9
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 6.8
Leverage Ratio 1.2
Quick Ratio 6.5
Long Term Debt To Capital 0.02
Assets
Receivables Turnover 3.4
Invoice Turnover 3.10
Assets Turnover 0.20
Management Effectiveness
Return Assets -69.05
Return On Equity -81.96
Return On Capital -79.26
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACAD
Acadia Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.